A chicken-derived serum of type 7 Riemerella anatipestifer and its application

By providing chicken-derived serum of Riemerella anatipestifer type 7 (HD24) and its application, an inactivated vaccine was prepared, solving the problem of chicken-derived RA vaccine shortage, achieving effective control of RA infection in chicken flocks, and providing high-quality strain materials and theoretical basis.

CN122278713APending Publication Date: 2026-06-26POULTRY INSTITUTE SHANDONG ACADEMY OF AGRICULTURAL SCIENCE (SHANDONG SPECIFIC PATHOGEN FREE CHICKS RESEARCH CENTER)
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
POULTRY INSTITUTE SHANDONG ACADEMY OF AGRICULTURAL SCIENCE (SHANDONG SPECIFIC PATHOGEN FREE CHICKS RESEARCH CENTER)
Filing Date
2026-04-28
Publication Date
2026-06-26

AI Technical Summary

Technical Problem

In the current technology, there is insufficient development of vaccines for genotype 7 anatipestifer from chicken serum, and the vaccines are not very specific, which makes it difficult to control anatipestifer infection in chicken flocks, and the overuse of antibiotics has led to serious problems of multidrug resistance.

Method used

This invention provides a chicken-derived serum of type 7 duck plague Riemerella dysenteriae HD24 and its application, for the preparation of water-in-oil, oil-in-water, or water-in-oil-in-water inactivated vaccines, and reveals its genetic differentiation patterns and pathogenicity through whole-genome research, which can be used to prepare detection reagents and vaccines.

Benefits of technology

This strain exhibits good immunoprotection and provides a candidate strain for chicken-derived RA inactivated vaccine, solving the problem of vaccine scarcity, providing a new technical solution for the prevention and control of RA infection in chicken flocks, and enriching the genetic evolution database of RA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122278713A_ABST
    Figure CN122278713A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of veterinary biological products technology, specifically relating to a chicken-derived serum type 7 of *Rimerella anatipestifer* and its application. *Rimerella anatipestifer* (… Riemerella anatipestifer HD24 has been deposited at the China General Microbiological Culture Collection Center (CGMCC) on March 18, 2026, with accession number CGMCC No. 37707. The inactivated vaccine using the HD24 strain exhibits an 80% immunoprotective rate, demonstrating its good immunogenicity and safety. This provides an ideal candidate strain for the development of inactivated chicken rabies (RA) vaccines, addressing the current shortage and lack of specificity of chicken-derived RA vaccines, and offering a new technical solution for the proactive prevention and control of RA infection in chicken flocks.
Need to check novelty before this filing date? Find Prior Art